Form 4: Spyre Therapeutics CEO Granted 528,000 Stock Options

Spyre Therapeutics' CEO, Cameron Turtle, was granted 528,000 stock options with an exercise price of $30.61, vesting over four years.

Summary

• Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics, Inc. (SYRE), was granted 528,000 stock options.
• The stock options have an exercise price of $30.61 per share.
• The grant date for these options was January 9, 2026.
• The options will vest in equal monthly installments over a four-year period, contingent on Mr. Turtle's continued employment with the Issuer.
• The options expire on January 9, 2036.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of significant stock options to the CEO is generally a positive signal, aligning management's interests with shareholders and indicating confidence in future growth. However, it's a standard compensation event rather than a direct operational or financial performance update.

Positives

• The grant of a significant number of stock options (528,000 shares) to the CEO aligns management's interests with long-term shareholder value.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation structure.

Negatives

• NA

Risks

• The vesting of the options is subject to the CEO's continued employment, posing a risk to the CEO's full realization of the options if employment ceases.
• The value of the options is dependent on the future stock price of Spyre Therapeutics exceeding the exercise price of $30.61, introducing market risk.

Future Outlook

The vesting schedule of the stock options over four years indicates a long-term incentive structure for the CEO, aligning future performance with equity realization and encouraging sustained leadership.

Management Comments

• NA

Industry Context

This executive compensation grant is a standard practice in the biotechnology and pharmaceutical industry to attract and retain top talent, aligning executive incentives with long-term company performance and shareholder value creation. The vesting schedule encourages sustained leadership and strategic execution in a highly competitive sector where long development cycles are common.

Comparison to Industry Standards

• The grant of 528,000 stock options to a CEO is a substantial equity award, common for leaders in growth-oriented biotech companies like Spyre Therapeutics, Inc., especially given the long development cycles and high-risk, high-reward nature of the industry.
• The four-year vesting schedule is a standard industry practice designed to retain executives and incentivize long-term value creation, comparable to compensation structures seen at peers such as Moderna (MRNA) or BioNTech (BNTX) for their executive teams, though specific numbers vary by company size and stage.
• The use of a Rule 10b5-1 plan for this transaction reflects a commitment to transparent and pre-planned equity transactions, a best practice in corporate governance widely adopted across the S&P 500.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the CEO's incentives lead to strong company performance, balanced by potential future dilution upon option exercise.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.
• Management: The CEO's compensation is now more directly tied to the company's stock performance, incentivizing strategic decisions that enhance share value.

Next Steps

• Continued vesting of the 528,000 stock options in equal monthly installments over four years, subject to the CEO's continued employment.
• Potential exercise of options by the CEO at or after vesting dates, prior to the expiration date of January 9, 2036.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, Stock Options, CEO Compensation, SEC Form 4, Equity Grant, Executive Compensation, Rule 10b5-1